The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon α-2a therapy. The efficacy of and compliance to peginterferon α-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods:Hepatitis B patients treated with peginterferon α-2a from 2008to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients,10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period,15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon α-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals,but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies
Abstract
Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon α-2a therapy. The efficacy of and compliance to peginterferon α-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods:Hepatitis B patients treated with peginterferon α-2a from 2008to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients,10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period,15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon α-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals,but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies
참고문헌 (19)
- Buster EH, "Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa", Gastroenterology, 137, pp.2002~2009 (2009)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Song BC, "Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection", Intervirology, 48, pp.133~137 (2005)
- Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
- Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
- Kao JH, "Hepatitis B genotypes and the response to interferon therapy", J Hepatol, 33, pp.998~1002 (2000)
- "Serum HBsAg Levels During Peginterferon alpha-2a Treatment With or Without Thymosin alpha-1 in HBeAg-Positive Chronic Hepatitis B Patients", JOURNAL OF MEDICAL VIROLOGY, 83, pp.88~94 (2011), WILEY-LISS
- Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
- Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Papatheodoridis GV, "The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B", J Hepatol, 34, pp.306~313 (2001)
- Lampertico P, "Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy", Hepatology, 37, pp.756~763 (2003)
- Manesis EK, "Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B", Gastroenterology, 121, pp.101~109 (2001)
- Rijckborst V, "A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B", Am J Gastroenterol, 105, pp.1762~1769 (2010)
- Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
- Liaw YF, "Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C", Hepatology, 54, pp.1591~1599 (2011)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Piratvisuth T, "Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int", Epub (2011)[DOI]
- Ratnam D, "Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience", J Gastroenterol Hepatol, 27, pp.1447~1453 (2012)